证券研究报告 利安隆 (300596 CH) 25Q1 业绩稳健，多元布局助力成长 | 华泰研究 | | | 季报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 28 日│中国内地 | 化学制品 | 公司公布一季度业绩：实现收入 15 亿元，同环比+9%/+4%；归母净利润 1 亿元，同环比+0.7%/-4%，公司 25Q1 净利与我们业绩前瞻基本一致（1 亿元）。 我们维持前次盈利预测。考虑公司新建项目逐步爬坡释放，电子级 PI 与生命 科学板块产业化持续推进，预计公司未来仍有增长空间。维持"增持"评级。 25Q1 业绩稳健，助剂业务再接再厉 公司加强下游市场开拓，25Q1业绩表现稳健。一季度公司毛利率为 21.52%， 同环比基本持平；综合费用率为 12%，同环比-0.04/+1.47pct，环比增加主 要是研发费用增加所致。据公司公告，公司拟在马来西亚建设研发生产基地， 生产销售抗老化添加剂与润滑油添加剂。海外公司的设立有助于进一步落实 公司国际化战略布局，提升公司的综合竞争力和抗风险能力。据海关总署， 25Q1 辽宁省润滑油添加剂出口量 0.77 万吨， ...

2025 年第一季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天津利安隆新材料股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第四届董事会第二十次会议、第四届监事会第十八次会议，审议通过了《关 于公司 2025 年第一季度报告的议案》。 为使投资者全面了解本公司的经营成果及财务状况，公司《2025 年第一季 度报告》已于 2025 年 4 月 29 日在中国证监会指定的信息披露网站巨潮资讯网 （www.cninfo.com.cn）上披露，敬请投资者注意查阅。 证券代码：300596 证券简称：利安隆 公告编号：2025-032 天津利安隆新材料股份有限公司 董事会 2025 年 4 月 29 日 特此公告。 天津利安隆新材料股份有限公司 ...

证券代码：300596 证券简称：利安隆 公告编号：2025-034 天津利安隆新材料股份有限公司 第四届监事会第十八次会议决议公告 本公司及全体监事会成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 会议召开情况 天津利安隆新材料股份有限公司（以下简称"公司"）第四届监事会第十八 次会议通知已于 2025 年 4 月 25 日以电话及电子邮件的形式发出，会议通知中包 括会议的相关资料，同时列明会议的召开时间、地点、内容和方式。会议于 2025 年 4 月 28 日上午 11:00 在公司会议室以现场方式召开，采取现场记名投票方式 进行表决。本次会议应出席监事 3 名，实际出席监事 3 名，会议由监事会主席丁 欢女士主持。本次会议的召集、召开及表决程序符合《中华人民共和国公司法》 及《公司章程》的有关规定，合法有效。 审议通过了《关于公司 2025 年第一季度报告的议案》 经审议，监事会认为：公司董事会编制和审核的公司《2025 年第一季度报 告》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完 整地反映了公司的实际经营情况，不存在任何虚假记载、误导性陈述 ...

证券代码：300596 证券简称：利安隆 公告编号：2025-033 天津利安隆新材料股份有限公司 第四届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 会议召开情况 天津利安隆新材料股份有限公司（以下简称"公司"）第四届董事会第二十 次会议通知已于 2025 年 4 月 25 日以电话及电子邮件的形式发出，会议通知中包 括会议的相关资料，同时列明会议的召开时间、地点、内容和方式。会议于 2025 年4月28日上午10:00以现场会议及通讯会议相结合的方式在公司会议室召开， 采用现场投票和通讯表决相结合的方式进行表决。本次会议应出席董事 11 名， 实际出席董事 11 名。会议由董事长李海平先生主持，公司监事、高级管理人员 列席会议。本次会议的召开和表决程序符合《中华人民共和国公司法》等法律、 法规和《公司章程》的有关规定。 审议通过了《关于公司 2025 年第一季度报告的议案》 经审议，公司董事会认为：公司《2025 年第一季度报告》的编制和审核的程 序符合相关法律法规，报告内容真实、准确、完整地反映了公司 2025 年第一 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,481,072,523.29, representing a 9.36% increase compared to ¥1,354,264,127.02 in the same period last year[6] - Net profit attributable to shareholders was ¥107,901,126.79, a slight increase of 0.71% from ¥107,137,289.03 year-on-year[6] - Total operating revenue for the first quarter of 2025 was CNY 1,481,072,523.29, an increase of 9.35% compared to CNY 1,354,264,127.02 in the previous year[26] - Net profit for the first quarter was CNY 104,330,900.23, slightly up from CNY 104,268,741.80 year-over-year[27] - The total comprehensive income attributable to the parent company was 107,464,747.16, compared to 106,461,050.00 in the previous period, reflecting an increase of approximately 0.94%[28] - Basic and diluted earnings per share were both 0.4699, up from 0.4666 in the previous period, indicating a growth of about 0.71%[28] Cash Flow - The net cash flow from operating activities was -¥138,402,771.45, a significant decline of 459.53% compared to -¥24,735,666.60 in the previous year[14] - Cash inflow from operating activities was 1,202,085,080.51, an increase from 1,098,880,171.69, representing a growth of approximately 9.42%[29] - Cash inflow from investment activities was 300,721,359.56, down from 475,325,064.29, a decrease of about 36.69%[30] - Net cash flow from investment activities was 1,238,593.74, a significant improvement from -273,005,204.08 in the previous period[30] - Cash inflow from financing activities totaled 909,099,415.58, compared to 632,154,439.79, marking an increase of approximately 43.93%[30] - Net cash flow from financing activities was 258,729,319.32, down from 540,698,671.37, indicating a decrease of about 52.14%[30] - The ending cash and cash equivalents balance was 1,038,798,663.30, down from 1,173,505,501.49, reflecting a decrease of approximately 11.45%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,409,638,191.46, up 3.02% from ¥9,134,140,669.49 at the end of the previous year[6] - Total liabilities increased to CNY 4,552,222,338.48, up from CNY 4,408,027,296.29, indicating a rise of 3.26%[24] - The company's equity attributable to shareholders reached CNY 4,570,597,937.83, compared to CNY 4,459,356,235.31, marking an increase of 2.5%[24] - As of March 31, 2025, total current assets amount to approximately ¥4.64 billion, an increase from ¥4.35 billion at the beginning of the period[22] - The company's cash and cash equivalents at the end of the period are approximately ¥1.30 billion, up from ¥1.07 billion at the beginning of the period[22] - Accounts receivable stand at approximately ¥1.21 billion, compared to ¥1.11 billion at the beginning of the period[22] - Inventory has increased to approximately ¥1.42 billion from ¥1.33 billion at the beginning of the period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,771[16] - The largest shareholder, Tianjin Lianlong Technology Group Co., Ltd., holds 14.14% of shares, totaling 32,461,290 shares[16] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Lianlong International Group Co., Ltd., holding 10.91%[16] - The company has a total of 4,931,157 restricted shares held by executive Han Borui, which remain locked under management regulations[19] Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[6] - The company plans to establish a wholly-owned subsidiary in Singapore and a subsidiary in Malaysia, with a total investment not exceeding $300 million for R&D and production facilities[21] - The company has completed the establishment of its Singapore and Malaysia subsidiaries as of the announcement date[21] Expenses - Total operating costs rose to CNY 1,352,618,360.08, up 9.25% from CNY 1,237,893,315.14 in the same period last year[26] - Research and development expenses for the quarter were CNY 69,650,294.39, up from CNY 61,498,271.29, representing a growth of 13.5%[26] - The company reported a financial expense of CNY 3,162,669.16, significantly down from CNY 10,583,764.51, a decrease of approximately 70%[26] Other Information - The weighted average return on equity decreased to 2.39% from 2.57% year-on-year[6] - The company received government subsidies amounting to ¥6,538,645.54, which positively impacted the net profit[7] - Investment income decreased by 82.15% to ¥206,870.49, mainly due to reduced returns from floating wealth management products[12] - The total non-current assets were CNY 4,768,946,698.27, slightly down from CNY 4,784,483,418.42, a decrease of 0.32%[24] - The company's long-term borrowings increased to CNY 1,551,289,913.06 from CNY 1,475,297,765.06, reflecting a growth of 5.15%[24] - The company did not undergo an audit for the first quarter report[31]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved revenue and profit growth in 2024, with a revenue of 5.687 billion yuan, up 7.7% year-on-year, and a net profit attributable to shareholders of 426 million yuan, up 17.6% year-on-year [6][8] - The company is expanding its global marketing strategy and has successfully increased its market presence, particularly in the high-margin polymer materials sector [8][12] - The company has completed the construction and production of its second phase of capacity in its lubricant additive subsidiary, which has improved overall capacity utilization [8][12] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 56.87 billion yuan, a year-on-year increase of 7.7%, and a net profit of 4.26 billion yuan, reflecting a 17.6% increase [6][8] - The fourth quarter of 2024 saw revenue of 1.422 billion yuan, which was stable year-on-year but down 1.6% quarter-on-quarter, while net profit rose by 41.3% year-on-year to 112 million yuan [7][11] Product Segmentation - The polymer materials segment achieved a sales volume of 123,600 tons, a 6.4% increase year-on-year, with a slight price decrease of 0.6% to 37,200 yuan per ton [8] - Revenue from light stabilizers reached 2.086 billion yuan, up 11.3% year-on-year, while antioxidant revenue was 1.730 billion yuan, up 8.0% year-on-year [8][17] Future Outlook - The company is expected to achieve revenues of 6.750 billion yuan, 7.841 billion yuan, and 8.415 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 510 million yuan, 595 million yuan, and 657 million yuan [13][15] - The projected PE ratios for 2025, 2026, and 2027 are 13, 11, and 10 times respectively, indicating a favorable valuation outlook [13][15]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company achieved a revenue of 5.69 billion yuan in 2024, representing a year-on-year increase of 7.7%. The net profit attributable to shareholders was 430 million yuan, up 17.6% year-on-year, and the net profit after deducting non-recurring gains and losses was 410 million yuan, an increase of 19.7% year-on-year. In Q4 alone, the company generated a revenue of 1.42 billion yuan, which was flat year-on-year but down 1.6% quarter-on-quarter. The net profit for Q4 was 110 million yuan, up 41.3% year-on-year and 19.8% quarter-on-quarter [2][6][10]. - The company plans to distribute a cash dividend of 3.7 yuan per 10 shares, totaling 84.96 million yuan [2][6]. - The company is expanding its production capacity and product lines, focusing on three growth curves: polymer aging agents, lubricant additives, and life sciences, which are expected to drive future growth [10][10]. Summary by Sections Financial Performance - In 2024, the company reported a total revenue of 5.69 billion yuan, with a gross margin of 21.2%, an increase of 1.5 percentage points year-on-year. The sales volume of polymer aging agents reached 124,000 tons, up 6.4% year-on-year, while lubricant additives saw a sales volume of 58,000 tons, up 23.2% year-on-year [10]. - The average price of polymer aging agents was 37,200 yuan per ton, with antioxidant revenue of 1.73 billion yuan (up 8.0%) and light stabilizer revenue of 2.09 billion yuan (up 11.3%) [10]. - The company’s total expenses as a percentage of revenue were 11.8%, with slight increases in sales, management, and R&D expenses [10]. Growth Strategies - The company is enhancing its production capabilities across six major production bases, ensuring stable growth in its main business. It has also innovated in the lubricant additives sector with a unique "additive supermarket" model [10]. - The life sciences division is focusing on synthetic biology and high-end electronic materials, with plans for further expansion and capacity building in these areas [10]. Future Outlook - The company is expected to see continued revenue and profit growth, with projected net profits of 540 million yuan, 630 million yuan, and 740 million yuan for 2025, 2026, and 2027, respectively [10].

证券代码：300596 证券简称：利安隆 公告编号：2025-030 天津利安隆新材料股份有限公司 关于控股股东部分股份解除质押的公告 控股股东天津利安隆科技集团有限公司保证向公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： ●天津利安隆新材料股份有限公司（以下简称"公司"）控股股东天津利安隆科 技集团有限公司（以下简称"利安隆集团"）持有本公司股份为 32,461,290 股，占 公司总股本的 14.14%，本次解除质押前累计质押股份数量为 18,486,200 股，本次解 除质押后累计质押股份数量为 16,086,200 股，占其持有公司股份总数的 49.56%，占 公司总股本的 7.01%。 ●控股股东一致行动人利安隆国际集团有限公司（以下简称"利安隆国际"）持 有本公司股份为 25,059,240 股，占公司总股本的 10.91%，其中被质押的股份累计 0 股，占其持有公司股份总数的 0.00%，占公司总股本的 0.00%。 ●截至本公告日，控股股东、实际控制人及 ...

证券代码：300596 证券简称：利安隆 公告编号：2025-029 天津利安隆新材料股份有限公司 一、本次股东股份质押的基本情况 | | 是否为 | | | | 是否为 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 第一大 | 本次质 | 占其 | 占公 | 限售股 | 是否 | | | | | | 股东 | 股东及 | 押股份 | 所持 | 司总 | （如 | 为补 | 质押起始 | 质押到期日 | 质权人 | 质押 | | 名称 | | 数量 | 股份 | 股本 | 是，注 | 充质 | 日 | | | 用途 | | | 其一致 行动人 | （股） | 比例 | 比例 | 明限售 | 押 | | | | | | | | | | | 类型） | | | | | | | 利安隆集团 | 是 | 880,200 | 2.71% | 0.38% | 否 | 否 | 2025/4/22 | 2026/4/21 | 渤海证券股 | 融资 | | | | | | | | | | | 份有限公司 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 5.687 billion yuan in 2024, representing a year-on-year growth of 7.74%, and a net profit attributable to shareholders of 426 million yuan, up 17.61% year-on-year. The Q4 revenue was 1.422 billion yuan, with a slight year-on-year increase of 0.04% and a quarter-on-quarter decrease of 1.62%. The net profit for Q4 was 112 million yuan, showing a significant year-on-year increase of 41.32% and a quarter-on-quarter increase of 19.75%. The company plans to distribute a cash dividend of 0.37 yuan per share (tax included) [4][6] - The company is focusing on solidifying its operations in antioxidant agents, lubricant additives, and life sciences while advancing the localization of PI materials, aiming for multi-level high-quality development [4][6] Financial Summary - The total revenue for 2023 was 5.278 billion yuan, with a year-on-year growth of 9.0%. The projected revenue for 2024 is 5.687 billion yuan, with a growth rate of 7.7%, and for 2025, it is expected to reach 6.259 billion yuan, reflecting a growth of 10.1% [6][8] - The net profit attributable to shareholders for 2023 was 362 million yuan, with a year-on-year decrease of 31.0%. The forecast for 2024 is 426 million yuan, up 17.6%, and for 2025, it is projected to be 516 million yuan, representing a growth of 21.0% [6][8] - The gross margin for 2024 is expected to be 21.2%, an increase of 1.46 percentage points year-on-year, while the net margin is projected to be 7.3%, up 0.51 percentage points year-on-year [6][8] Business Segmentation - In 2024, the company’s revenue from antioxidant agents, light stabilizers, U-pack, and lubricant additives was 1.730 billion yuan, 2.086 billion yuan, 614 million yuan, and 1.063 billion yuan respectively, with year-on-year growth rates of 7.99%, 11.31%, -3.77%, and 15.40% [4][6] - The sales volume for antioxidant agents and lubricant additives was 123,600 tons and 58,300 tons respectively, with year-on-year increases of 6.40% and 23.23% [4][6] - The life sciences business generated revenue of 3.63 million yuan, indicating a transition from research and development to dual-track operations involving both R&D and market [4][6] Valuation Metrics - The projected earnings per share (EPS) for 2025 is 2.25 yuan, with corresponding price-to-earnings (P/E) ratios of 12.6, 10.9, and 9.7 for 2025, 2026, and 2027 respectively [4][6][8] - The company’s return on equity (ROE) is expected to improve from 8.4% in 2023 to 10.4% by 2027 [6][8]